Adoption of Injectable Naltrexone in U.S. Substance Use Disorder Treatment Programs

Abstract

ABSTRACT. Objective: Medication-assisted treatment for substance use disorders (SUDs) is not widely used in treatment programs. The aims of the current study were to document the prevalence of adoption and implementation of extended-release injectable naltrexone, the newest U.S. Food and Drug Administration-approved medication for alcohol use disorder (AUD), in U.S. treatment programs and to examine associations between organizational and patient characteristics and adoption. Method: The study used interview data from a nationally representative sample of 307 U.S. SUD treatment programs to examine adoption and implementation of injectable naltrexone. Results: Thirteen percent of programs used injectable naltrexone for AUD, and 3% of programs used it for opioid use disorder. Every treatment program that offered injectable naltrexone to its patients used it in conjunction with psychosocial treatment, particularly cognitive behavioral therapy. Multivariate logistic regression results indicated that adoption was positively associated with the provision of wraparound services, the percentage of privately insured patients, and the presence of inpatient detoxifi cation services. For-profi t status and offering inpatient services were negatively associated with adoption. Within adopting programs, an average of 4.1% of AUD patients and 7.1% of patients with opioid use disorder were currently receiving the medication, despite clinical directors' reports of positive patient outcomes, particularly for relapsers and for those who had been noncompliant with other medications. Cost was a signifi cant issue for the majority of adopting organizations. Conclusions: The rate of adoption of injectable naltrexone in U.S. treatment programs remains limited. Researchers should continue to examine patient, organizational, and external characteristics associated with the adoption and implementation of injectable naltrexone over time. (J. Stud. Alcohol Drugs, 76, 143-151, 2015)

Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis

“…Past research finds a higher prevalence of testing for HIV and sexually transmitted infections in non-profit treatment programs (D'Aunno et al 2014; Guerrero & Cederbaum, 2011). Further, several studies find that for-profit SUD treatment programs offer fewer core services as well as wraparound services, such as medical care (Aletraris, Bond Edmond, & Roman, 2015; Ducharme, Mello, Roman, Knudsen, & Johnson, 2007; Friedmann, Lemon, Durkin, & D'Aunno, 2003). …”

Developing an opioid use disorder treatment cascade: A review of quality measures

“…Unintentional overdose death is often a consequence of untreated or improperly treated opioid use disorder (OUD), reflecting a long-standing addiction treatment gap in the United States and the difficulties patients face in accessing evidence-based care (Ghitza & Tai, 2014; Volkow, Friedan, Hyde, & Cha, 2014). Despite FDA approval of three effective medications (methadone, buprenorphine, and XR-naltrexone) shown to reduce overdose among patients with OUD (Degenhardt, Bucello, Mathers, et al, 2010; Lee, Friedmann, Kinlock, et al, 2016; Lee, Nunes, Novo, et al, 2018), there remain low rates of initiation and retention on these medications (Aletraris, Bond, & Roman, 2015; Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016; Turner, Kruszewski, & Alexander, 2015). An alarmingly low percentage - barely a fifth - of the 2.4 million individuals estimated to have OUD (SAMHSA, 2017) receive any specialty care in a given year (Saloner, 2015; Wu, Zhu, & Swartz, 2016).…”

Implementation of smoking cessation treatment in substance use disorder treatment settings: a review

“…Yet relatively few organizations offer counseling-based tobacco treatment, and few clinicians regularly counsel tobacco-using patients. The limited implementation of pharmacotherapy is perhaps more understandable, given that few SUD organizations offer medications for alcohol and opioid use disorder (83), and even within adopting organizations, few patients actually receive pharmacotherapy (84)(85)(86). As noted in a recent commentary (87), tobacco cessation is something that patients must "opt in" to (if they are even given that choice) rather than having cessation services as the norm from which patients can "opt out.…”